29.50
0.80 (2.79%)
| Penutupan Terdahulu | 28.70 |
| Buka | 29.00 |
| Jumlah Dagangan | 413,623 |
| Purata Dagangan (3B) | 635,322 |
| Modal Pasaran | 1,406,003,456 |
| Harga / Buku (P/B) | 2.77 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| EPS Cair (TTM) | -3.82 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.74% |
| Nisbah Semasa (MRQ) | 31.01 |
| Aliran Tunai Operasi (OCF TTM) | -67.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -47.00 M |
| Pulangan Atas Aset (ROA TTM) | -22.89% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.14% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Rapport Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.70 |
|
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 6.28% |
| % Dimiliki oleh Institusi | 105.23% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Trv Gp V, Llc | 30 Sep 2025 | 7,135,233 |
| Arch Venture Management, Llc | 30 Sep 2025 | 3,728,738 |
| Sofinnova Investments, Inc. | 30 Sep 2025 | 1,947,579 |
| Trv Gp Vi, Llc | 30 Sep 2025 | 969,218 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 80.00 (Citizens, 171.19%) | Beli |
| Median | 45.50 (54.24%) | |
| Rendah | 34.00 (HC Wainwright & Co., 15.25%) | Beli |
| Purata | 51.25 (73.73%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 28.21 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 08 Dec 2025 | 47.00 (59.32%) | Beli | 29.50 |
| 19 Nov 2025 | 47.00 (59.32%) | Beli | 26.88 | |
| Citizens | 07 Nov 2025 | 80.00 (171.19%) | Beli | 25.66 |
| Truist Securities | 16 Sep 2025 | 44.00 (49.15%) | Beli | 26.19 |
| HC Wainwright & Co. | 08 Sep 2025 | 34.00 (15.25%) | Beli | 31.47 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| GAULT CHERYL | - | 29.43 | -5,000 | -147,150 |
| Jumlah Keseluruhan Kuantiti Bersih | -5,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -147,150 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 29.43 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| GAULT CHERYL | Pegawai | 26 Nov 2025 | Jual automatik (-) | 5,000 | 29.43 | 147,150 |
| GAULT CHERYL | Pegawai | 26 Nov 2025 | Pelaksanaan pilihan | 5,000 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |